4//SEC Filing
Solomons Neil 4
Accession 0001628280-21-018594
CIK 0001600620other
Filed
Sep 13, 8:00 PM ET
Accepted
Sep 14, 5:11 PM ET
Size
9.0 KB
Accession
0001628280-21-018594
Insider Transaction Report
Form 4
Solomons Neil
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Shares
2021-09-13$3.20/sh+150,000$480,000→ 287,299 total - Sale
Common Shares
2021-09-10$19.84/sh−150,000$2,976,000→ 137,299 total - Exercise/Conversion
Stock Option (right to buy)
2021-09-13−150,000→ 2,000 totalExercise: $3.20Exp: 2027-02-09→ Common Stock (150,000 underlying)
Footnotes (4)
- [F1]Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $19.77 to $19.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F4]The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date.
Documents
Issuer
Aurinia Pharmaceuticals Inc.
CIK 0001600620
Entity typeother
Related Parties
1- filerCIK 0001837720
Filing Metadata
- Form type
- 4
- Filed
- Sep 13, 8:00 PM ET
- Accepted
- Sep 14, 5:11 PM ET
- Size
- 9.0 KB